Article
Association of CYP3A5*3, CYP3A4*18 & CYP2B6*6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients.
The Indian journal of medical research - 1 Aug 2023
Asadov Chingiz, Karimova Nigar, Hasanova Aypara, Bayramov Bayram, Shirinova Aytan, Alimirzoyeva Zohra
Abstract excerpt
Background & objectives: Imatinib mesylate (IM) is a reliable first line treatment for chronic myeloid leukaemia (CML). Nevertheless, despite promising results, a considerable proportion of patients develop resistance to the drug. Cytochrome P450 (CYP) enzymes play a crucial role in IM metabolism. Thus, point mutations in CYP genes may modify IM enzyme activity resulting in insufficient treatment response. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.